title: Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery.
abstract: The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.
authors.affiliation: John A. Moran Eye Center, University of Utah School of Medicine, 65 Mario Capecchi Drive, S5668, Salt Lake City, UT, 84132, USA.
authors.forename: Andrew Xingyu
authors.initials: AX
authors.lastname: Zhou
authors.affiliation: John A. Moran Eye Center, University of Utah School of Medicine, 65 Mario Capecchi Drive, S5668, Salt Lake City, UT, 84132, USA.
authors.forename: Wyatt Boyer
authors.initials: WB
authors.lastname: Messenger
authors.affiliation: John A. Moran Eye Center, University of Utah School of Medicine, 65 Mario Capecchi Drive, S5668, Salt Lake City, UT, 84132, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Sargent
authors.affiliation: John A. Moran Eye Center, University of Utah School of Medicine, 65 Mario Capecchi Drive, S5668, Salt Lake City, UT, 84132, USA. bala.ambati@utah.edu.
authors.forename: Balamurali Krishna
authors.initials: BK
authors.lastname: Ambati
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000867:Anterior Chamber / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D019072:Antibiotic Prophylaxis; D009877:Endophthalmitis / Q000517:prevention & control*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D019055:No-Observed-Adverse-Effect Level; D009883:Ophthalmic Solutions; D018918:Phacoemulsification; D012189:Retrospective Studies; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009883:Ophthalmic Solutions; D000077266:Moxifloxacin
keywords: Cataract; Endophthalmitis; Intracameral; Moxifloxacin; Phacoemulsification